Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PPM1B | O75688 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70308 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL4249001 | 0.92 | CYP2D6 (0.44) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL6513544 | 0.90 | CHRM2 (0.42) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL6285175 | 0.90 | CHRM2 (0.42) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL6285170 | 0.90 | CHRM2 (0.42) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL7738552 | 0.88 | CHRM2 (0.41) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL7738558 | 0.88 | CHRM2 (0.41) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL20642398 | 0.87 | CHRM2 (0.43) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL16199255 | 0.87 | TSHR (0.51) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL8264682 | 0.82 | CHRM2 (0.44) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023717-A1 | MORPHINE-BRIDGED INDAZOLE DERIVATIVES | FEURER ACHIM | 2009-01-22 | — | — | US | disclosed |
| US-20090023717-A1 | MORPHINE-BRIDGED INDAZOLE DERIVATIVES | FEURER ACHIM | 2009-01-22 | — | — | US | disclosed |
| US-7427617-B2 | Morpoline-bridged indazole derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-23 | — | — | US | disclosed |
| US-7427617-B2 | Morpoline-bridged indazole derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-23 | — | — | US | disclosed |
| US-20060128700-A1 | e.g. 2-[1-(2-Fluorobenzyl)-1H-indazol-3-yl]-5-(3-oxa-9-azabicyclo[3.3.1]non-9-yl)-4pyrimidinylamine; soluble guanylate cyclase stimulant; neurodegenerative diseases, cognition activator; Alhzeimer's, Parkinson's disease, Pick's syndrome, multiple sclerosis, HIV dementia, schizophrenia | BAYER HEALTHCARE AG (DE) | 2006-06-15 | — | — | US | disclosed |
| US-20040235863-A1 | Morpholine-bridged pyrazolopyridine derivatives | BAYER HEALTHCARE AG (DE) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023717-A1 | MORPHINE-BRIDGED INDAZOLE DERIVATIVES | OPRM1, OPRK1, OPRD1 | CHRM2 140/4885CHRM4 132/4885CHRM3 15/4885 |
| US-20060128700-A1 | e.g. 2-[1-(2-Fluorobenzyl)-1H-indazol-3-yl]-5-(3-oxa-9-azabicyclo[3.3.1]non-9-yl)-4pyrimidinylamine; soluble guanylate cyclase stimulant; neurodegenerative diseases, cognition activator; Alhzeimer's, Parkinson's disease, Pick's syndrome, multiple sclerosis, HIV dementia, schizophrenia | GUCY1B2, COG4, GUCY1A2 | CHRM2 108/4885CHRM4 6/4885CHRM3 120/4885 |
| US-20040235863-A1 | Morpholine-bridged pyrazolopyridine derivatives | GUCY1A1, PDE1A, PDE3B | CHRM2 292/4885CHRM4 602/4885CHRM3 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.